China National Accord Medicines Corp Ltd
SZSE:000028
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
Market Cap | EV/EBIT | ||||
---|---|---|---|---|---|
CN |
C
|
China National Accord Medicines Corp Ltd
SZSE:000028
|
21.4B CNY | 12 | |
US |
Mckesson Corp
NYSE:MCK
|
73.3B USD | 18.9 | ||
US |
Cencora Inc
NYSE:COR
|
44.1B USD | 16.4 | ||
US |
Amerisourcebergen Corp
NYSE:ABC
|
35.4B USD | 15.2 | ||
US |
Cardinal Health Inc
NYSE:CAH
|
24B USD | 11.9 | ||
US |
Henry Schein Inc
NASDAQ:HSIC
|
9.4B USD | 17.5 | ||
KR |
C
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 61.9 | |
CN |
Sinopharm Group Co Ltd
HKEX:1099
|
66.9B HKD | 2.1 | ||
IT |
Amplifon SpA
MIL:AMP
|
7.6B EUR | 30.4 | ||
CN |
Huadong Medicine Co Ltd
SZSE:000963
|
57.5B CNY | 14.8 | ||
CN |
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
52B CNY | 8.5 |
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.